10-Q quarterly report · filed Nov 4, 2026

Vaxcyte, Inc. (PCVX) Q3 2026 10-Q Quarterly Report

Short answer

Vaxcyte, Inc. (PCVX) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$297M
−39.6% YoY · −4.5% QoQ
EPS (diluted)
−$1.99
−26.8% YoY · −1.5% QoQ

Source: XBRL data from the Vaxcyte, Inc. (PCVX) Q3 2026 10-Q on SEC EDGAR. USD.

Vaxcyte, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no approved products or commercial sales
  • Net loss $297.1M vs $212.8M YoY, operating loss $308.3M vs $242.4M
  • R&D expense $270.3M, up 28.8% YoY, driven by PCV manufacturing and OPUS trials
  • Cash, equivalents and investments $2.3B, including $0.1B cash and $2.1B investments
  • Operating cash outflow $737.2M; October offerings generated approximately $1.15B gross proceeds, outlook funding through at least 12 months

Risk Factors

  • Newly added AI risk: expanded operational use of AI could trigger privacy-law violations, regulatory scrutiny, or reputational harm
  • Most materially updated regulatory risk: FDA may require expanded trials, additional safety data, or post-marketing surveillance for vaccine approvals
  • Regulatory compliance risk: federal vaccine-policy changes could alter ACIP-linked coverage, reimbursement, liability protections, and state mandates
  • Competitive risk: Pfizer plans PCV25 pediatric Phase 3 completion in Q2 2029, with regulatory submission planned in 2029
  • Liquidity risk: $2.3 billion cash, cash equivalents, and investments expected to fund operations for at least 12 months

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Vaxcyte, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.